0
Sign In
|
POL Subscriptions
Home
DSM Library
DSM-IV-TR®
DSM-IV-TR® Handbook of Differential Diagnosis
DSM Cases
Books
The American Psychiatric Publishing Textbook of Psychiatry
Gabbard's Treatments of Psychiatric Disorders
Textbook of Psychotherapeutic Treatments
The American Psychiatric Publishing Textbook of Geriatric Psychiatry
Dulcan's Textbook of Child and Adolescent Psychiatry
The American Psychiatric Publishing Textbook of Substance Abuse Treatment
The American Psychiatric Publishing Textbook of Psychopharmacology
Manual of Clinical Psychopharmacology
Textbook of Traumatic Brain Injury
Journals
The American Journal of Psychiatry
Psychiatric Services
The Journal of Neuropsychiatry and Clinical Neurosciences
Academic Psychiatry
FOCUS
Psychiatric News
Topics
APA Guidelines
CME & Self-Assessment
News
For Patients
What Your Patients Need to Know About Psychiatric Medications
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts
Let's Talk Facts
My POL
Advanced Search
Home
Current Issue
All Issues
Topics
13
The American Journal of Psychiatry, VOL. 160, No. 6
1
AJP
Letter to the Editor
|
June 01, 2003
Randomized Controlled Trials
ASHOK KUMAR JAINER, M.D., M.R.C.Psych.; MOHAN CHAWLA, M.D., M.R.C.Psych.
Am J Psychiatry 2003;160:1189-1190.
10.1176/appi.ajp.160.6.1189
Article
References
text
A
A
A
To the Editor: We read with great interest the article by Murray B. Stein, M.D., and his colleagues
+
(1)
, which reported on a double-blind randomized study. Randomized controlled trials are always cited as the gold standard for detecting treatment efficacy. However, they often can be flawed in design and are not immune to bias. The relevance of such a study has been criticized on the grounds of small group size, selection bias, and improper random assignment to groups.
The authors failed to provide information about how many subjects were initially assessed, how many subjects were excluded from study, and any reasons for exclusion. We do know the rate of participation, the rate of response, and the implications for generalizability and future research. The selection of patients in randomized controlled trials has been a controversial issue. In this context, the guidelines for the Consolidated Standards of Reporting Trials (CONSORT) state that all patients assessed for trials should be accounted for and that the report should be accompanied by a diagram that explains what happened to all of the patients involved in the trial
+
(2)
.
Random allocation to intervention groups remains the only method of ensuring that groups being compared are on an equivalent footing at the outset of the study, thus eliminating allocation and confounding biases. In this particular article, information was lacking on both components of randomization, concealment and method. Improper randomization can introduce serious allocation bias. Assessment of the quality of randomization in published trials has consistently found flaws
+
(3
,
+
4)
. CONSORT guidelines have emphasized that methods of randomization should be clearly reported
+
(2)
. It has also been reported that trials with adequate or unclear allocation concealment may yield larger estimates of effect than those with inadequate concealment. This exaggerated estimate of treatment effects reveals a meaningful level of bias. In the absence of adequate information on the methods of randomization, the possibility of allocation bias may be raised. Elimination of bias would have been possible if the authors of this article had strictly followed CONSORT guidelines.
Finally, the authors failed to communicate effect size precisely. Since they presented their results almost solely as p values, it is difficult to understand their meaning. It is possible for small effect sizes to become statistically significant, which is evident in this study. However, it is the precision of effect size rather than the level of significance that determines how much faith a critical reader will have in the authors’ results. We also do not know the response rate and the remission rate, which determine the clinical importance of the results.
References
References
1
+
Stein MB, Kline NA, Matloff JL: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002; 159:1777-1779
[PubMed]
[CrossRef]
2
+
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276:637-639
[PubMed]
[CrossRef]
3
+
Schulz KF, Chalmers I, Grimes DA, Altman DG: Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994; 272:125-128
[PubMed]
[CrossRef]
4
+
Altman DG, Dore CJ: Randomization and baseline comparisons in clinical trials. Lancet 1990; 335:149-153
[PubMed]
[CrossRef]
+
1
+
Stein MB, Kline NA, Matloff JL: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002; 159:1777-1779
[PubMed]
[CrossRef]
2
+
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276:637-639
[PubMed]
[CrossRef]
3
+
Schulz KF, Chalmers I, Grimes DA, Altman DG: Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994; 272:125-128
[PubMed]
[CrossRef]
4
+
Altman DG, Dore CJ: Randomization and baseline comparisons in clinical trials. Lancet 1990; 335:149-153
[PubMed]
[CrossRef]
+
+
CME Activity
There is currently no quiz available for this resource. Please
click here to go to the CME page
to find another.
Loading...
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.
*
= Required Field
Comment Author(s)
*
(if multiple authors, separate names by comma)
Example: John Doe
Affiliation & Institution
*
Comment Title
*
Comment
*
Cancel
Print
E-mail
Recipient(s) will receive an email with a link (good for 72 hours) to '
Randomized Controlled Trials
' and do not need to have American Journal of Psychiatry account to access the content.
Your Name:
*
Example: John Doe
Email Address:
*
CC Me:
Enter your valid email address. Example: jdoe@example.com
Recipient's Email Address:
*
Separate multiple email address with semi-colons (up to 5).
Subject:
*
's American Journal of Psychiatry: 'Randomized Controlled Trials'
Subject for your email.
Message:
(Optional, message will truncate at 1000 characters)
Processing your request... Please Wait...
Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's
Terms of Use
. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's
Privacy Policy
for further information.
Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation
ASHOK KUMAR JAINER, MOHAN CHAWLA; Randomized Controlled Trials. American Journal of Psychiatry. 2003 Jun;160(6):1189-1190.
Download citation file:
RIS (Zotero)
EndNote
BibTex
Medlars
ProCite
RefWorks
Reference Manager
Copyright © American Psychiatric Association. All rights reserved.
Reprints
Related Content
Articles
A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders
Am J Psychiatry 2 December 2011
[+] View More
Books
APA Practice Guidelines > Chapter 7. >
Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd Edition
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 63. >
Treatment of Child and Adolescent Disorders
APA Practice Guidelines > Chapter 6. >
Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition
APA Practice Guidelines > Chapter 5. >
Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients With Schizophrenia
APA Practice Guidelines > Chapter 0. >
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
[+] View More
Psychiatric News
Psychiatric News Home
Journal Digest
2 December 2011
Med Check
4 November 2011
Med Check
18 March 2011
Med Check
1 October 2010
‘Real-World’ Field Trials Next Step in
DSM-5
Process
1 October 2010
[+] View More
Read more at
Psychiatric News >>
APA Guidelines
Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd Edition
Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition
Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients With Schizophrenia
[+] View More
PubMed Articles
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2012 Jan 25
Low-molecular-weight heparin and mortality in acutely ill medical patients.
The New England journal of medicine 2011 Dec 29
You do not have access to this content.
You either do not have a subscription or your subscription has expired.
Click here
to Renew Now
Copyright ©
American
Psychiatric
Association